Tech Company Financing Transactions
Tempero Bio Funding Round
8VC, Aditum Bio and Khosla Ventures invested in a $70 million Series B venture round for Tempero Bio. This venture round was announced on 3/24/2025.
Transaction Overview
Company Name
Announced On
3/24/2025
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance TMP-301 through two Phase 2 clinical trials for alcohol use disorder and cocaine use disorder, as well as Phase 3-enabling activities and preclinical studies for additional indications and formulations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1111 Broadway 1300
Oakland, CA 94607
USA
Oakland, CA 94607
USA
Phone
Website
Email Address
Overview
Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for substance use disorders and related conditions. We're striving to help people with addiction overcome treatment obstacles and move forward on the path to a healthier life.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Ricardo Dolmetsch
Browse more venture capital transactions:
Prev: 3/23/2025: Browser Use venture capital transaction
Next: 3/24/2025: Campus venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs